NCT03283917View on ClinicalTrials.gov

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

May 18, 2027

Study Completion Date

May 18, 2027

Conditions
Newly Diagnosed Primary AmyloidosisRecurrent Primary AmyloidosisRefractory Primary Amyloidosis
Interventions
BIOLOGICAL

Daratumumab

Given IV

DRUG

Dexamethasone

Given IV or PO

DRUG

Ixazomib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

collaborator

Takeda

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT03283917 - Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis | Biotech Hunter | Biotech Hunter